Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021:35 Suppl 2:S530-S532.
doi: 10.1016/j.gaceta.2021.10.085.

Comorbidities and mortality in COVID-19 patients

Irawaty Djaharuddin  1 , Sitti Munawwarah  2 , Asvin Nurulita  3 , Muh Ilyas  2 , Nur Ahmad Tabri  2 , Nurjannah Lihawa  2
Affiliations

Comorbidities and mortality in COVID-19 patients

Irawaty Djaharuddin et al. Gac Sanit. 2021.

Abstract

Background: The high mortality rate in Coronavirus Disease (COVID-19) patients is associated with their comorbid conditions. Therefore, it is important to identify risk factors associated with poor outcomes among COVID-19 patients. The aims of this study were to find out the comorbidities in case of death due to COVID-19.

Methods: The design of this study was a retrospective descriptive method with a confirmed COVID-19 patient on hospitalized at Dr. Wahidin Sudirohusodo Hospital from March to September 2020. Ethics Council recommendation number: 357/UN4.6.4.5.31/PP36/2020.

Results: A total of 454 patients were included of this study. 78 (17.18%) patients death due to COVID-19, consisting of 52 (66.67%) male and 26 (33.33%) female. Range of ages between 18 and 85 years. The highest mortality rate occurred in the age group ≥60 years (35; 51.47%), followed by the age group of 45-59 years (33; 48.53%), and the age group of <45 years (10; 12%). The prevalent comorbidity was hypertension (42.31%), cardiovascular disease (30.77%), diabetes (28.21%), chronic kidney disease (23.08%), malignancy (15.38%), obesity (15.38%), chronic liver disease (7.69%), chronic respiratory disease (6.41%), immune related disease (3.85%), and non-traumatic cerebral infarction (3.85%). 41 (52.56%) patients reported having two or more comorbidities, and 37 (47.44%) only has one comorbidity. Elevated neutrophil-to-lymphocyte ratio (NLR) ≥3.13 was seen in the majority of patients (68; 87.18%). The mean value of NLR was 20.94.

Conclusions: Hypertension, cardiovascular disease, and diabetes were the most common comorbidity in patients death due to COVID-19. More than half of the patients had two or more comorbidities.

Keywords: COVID-19; Comorbidities; Mortality.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Outcome of confirmed COVID-19 patients.
Fig. 2
Fig. 2
Comorbidities of patients death due to COVID-19.
See this image and copyright information in PMC

References

    1. WHO. Coronavirus Disease 2019 Situation Report 51-11th March 2020. WHO Bull. 2020; 2019: 2633.
    1. WHO Indonesia. Coronavirus Disease Situation Report World Health Organization. World Heal Organ. 2020; 19:1–17.
    1. Hua W., Xiaofeng L., Zhenqiang B., et al. Consideration on the strategies during epidemic stage changing from emergency response to continuous prevention and control. Chinese J Endem. 2020;41:297–300. - PubMed
    1. Bialek S., Boundy E., Bowen V., et al. Severe outcomes among patients with coronavirus disease 2019 (COVID-19) — United States, February 12–March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:343–346. - PMC - PubMed
    1. Sanyaolu A., Okorie C., Marinkovic A., et al. Comorbidity and its impact on patients with COVID-19. SN Compr Clin Med. 2020;2:1069–1076. - PMC - PubMed